William Blair Initiates Coverage On Tarsus Pharmaceuticals with Outperform Rating, Announces Price Target of $44
Portfolio Pulse from richadhand@benzinga.com
William Blair has initiated coverage on Tarsus Pharmaceuticals (NASDAQ:TARS) with an Outperform rating and a price target of $44.
July 18, 2023 | 1:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tarsus Pharmaceuticals has received an Outperform rating from William Blair, with a price target set at $44.
The Outperform rating from William Blair indicates a positive outlook for Tarsus Pharmaceuticals. The price target of $44 suggests that the firm believes the stock has significant upside potential. This could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100